Overview

Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided,

Status:
Recruiting

Trial end date:
2024-12-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left-sided, unresectable colorectal cancer

Phase:

Phase 3

Details

Lead Sponsor:

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Collaborator:

Amgen

Treatments:

Antibodies, Monoclonal
Bevacizumab
Fluorouracil
Leucovorin
Oxaliplatin
Panitumumab